MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/0008-5472.can-11-3135

Медицинская библиотека · Cancer research · 2012

An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.

Huang Xiumei, Dong Ying, Bey Erik A, Kilgore Jessica A, Bair Joseph S, Li Long-Shan, Patel Malina, Parkinson Elizabeth I, Wang Yiguang, Williams Noelle S, Gao Jinming, Hergenrother Paul J, Boothman David A

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed. Here, we report that deoxynyboquinone kills a wide spectrum of cancer cells in an NQO1-dependent manner with greater potency than β-lapachone. Deoxynyboquinone lethality relies on NQO1-dependent futile redox cycling that consumes oxygen and generates extensive reactive oxygen species (ROS). Elevated ROS levels cause extensive DNA lesions, PARP1 hyperactivation, and severe NAD+ /ATP depletion that stimulate Ca2+ -dependent programmed necrosis, unique to this new class of NQO1 "bioactivated" drugs. Short-term exposure of NQO1+ cells to deoxynyboquinone was sufficient to trigger cell death, although genetically matched NQO1- cells were unaffected. Moreover, siRNA-mediated NQO1 or PARP1 knockdown spared NQO1+ cells from short-term lethality. Pretreatment of cells with BAPTA-AM (a cytosolic Ca2+ chelator) or catalase (enzymatic H2O2 scavenger) was sufficient to rescue deoxynyboquinone-induced lethality, as noted with β-lapachone. Investigations in vivo showed equivalent antitumor efficacy of deoxynyboquinone to β-lapachone, but at a 6-fold greater potency. PARP1 hyperactivation and dramatic ATP loss were noted in the tumor, but not in the associated normal lung tissue. Our findings offer preclinical proof-of-concept for deoxynyboquinone as a potent chemotherapeutic agent for treatment of a wide spectrum of therapeutically challenging solid tumors, such as pancreatic and lung cancers.

Для цитирования: Huang Xiumei, Dong Ying, Bey Erik A, Kilgore Jessica A, Bair Joseph S, Li Long-Shan, Patel Malina, Parkinson Elizabeth I, Wang Yiguang, Williams Noelle S, Gao Jinming, Hergenrother Paul J, Boothman David A. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.. Cancer research. 2012. DOI: 10.1158/0008-5472.can-11-3135.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.